Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 405

1.

Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O, Mazor G, Varon M, Hölting TLB, Grossetête S, Gartlgruber M, Surdez D, Gerke JS, Ohmura S, Marchetto A, Dallmayer M, Baldauf MC, Stein S, Sannino G, Li J, Romero-Pérez L, Westermann F, Hartmann W, Dirksen U, Gymrek M, Anderson ND, Shlien A, Rotblat B, Kirchner T, Delattre O, Grünewald TGP.

Nat Commun. 2019 Sep 11;10(1):4128. doi: 10.1038/s41467-019-12071-2.

2.

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations.

Durand S, Pierre-Eugène C, Mirabeau O, Louis-Brennetot C, Combaret V, Colmet-Daage L, Blanchard O, Bellini A, Daudigeos-Dubus E, Raynal V, Schleiermacher G, Baulande S, Delattre O, Janoueix-Lerosey I.

Oncotarget. 2019 Aug 13;10(48):4937-4950. doi: 10.18632/oncotarget.27119. eCollection 2019 Aug 13.

3.

STAG Mutations in Cancer.

Romero-Pérez L, Surdez D, Brunet E, Delattre O, Grünewald TGP.

Trends Cancer. 2019 Aug;5(8):506-520. doi: 10.1016/j.trecan.2019.07.001. Epub 2019 Jul 31. Review.

PMID:
31421907
4.

An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.

Morabito M, Larcher M, Cavalli FM, Foray C, Forget A, Mirabal-Ortega L, Andrianteranagna M, Druillennec S, Garancher A, Masliah-Planchon J, Leboucher S, Debalkew A, Raso A, Delattre O, Puget S, Doz F, Taylor MD, Ayrault O, Bourdeaut F, Eychène A, Pouponnot C.

EMBO Mol Med. 2019 Aug;11(8):e9830. doi: 10.15252/emmm.201809830. Epub 2019 Jul 22.

5.

Same-stage total knee arthroplasty and osteotomy for osteoarthritis with extra-articular deformity. Part II: Femoral osteotomy, prospective study of 6 cases.

Catonné Y, Khiami F, Sariali E, Ettori MA, Delattre O, Tillie B.

Orthop Traumatol Surg Res. 2019 Jun 13. pii: S1877-0568(19)30160-4. doi: 10.1016/j.otsr.2019.04.009. [Epub ahead of print]

PMID:
31204182
6.

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.

Bellini A, Bessoltane-Bentahar N, Bhalshankar J, Clement N, Raynal V, Baulande S, Bernard V, Danzon A, Chicard M, Colmet-Daage L, Pierron G, Le Roux L, Planchon JM, Combaret V, Lapouble E, Corradini N, Thebaud E, Gambart M, Valteau-Couanet D, Michon J, Louis-Brennetot C, Janoueix-Lerosey I, Defachelles AS, Bourdeaut F, Delattre O, Schleiermacher G.

Int J Cancer. 2019 Nov 15;145(10):2781-2791. doi: 10.1002/ijc.32361. Epub 2019 May 31.

PMID:
31018240
7.

SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation.

Blanluet M, Masliah-Planchon J, Giurgea I, Bielle F, Girard E, Andrianteranagna M, Clemenceau S, Bourneix C, Burglen L, Doummar D, Rapinat A, Oumoussa BM, Ayrault O, Pouponnot C, Gentien D, Pierron G, Delattre O, Doz F, Bourdeaut F.

Acta Neuropathol. 2019 Apr;137(4):675-678. doi: 10.1007/s00401-019-01983-4. Epub 2019 Mar 8. No abstract available.

PMID:
30848346
8.

ART-DeCo: easy tool for detection and characterization of cross-contamination of DNA samples in diagnostic next-generation sequencing analysis.

Fiévet A, Bernard V, Tenreiro H, Dehainault C, Girard E, Deshaies V, Hupe P, Delattre O, Stern MH, Stoppa-Lyonnet D, Golmard L, Houdayer C.

Eur J Hum Genet. 2019 May;27(5):792-800. doi: 10.1038/s41431-018-0317-x. Epub 2019 Jan 25.

PMID:
30683922
9.

Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility.

Machiela MJ, Grünewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, Zaidi S, Grossetete-Lalami S, Ballet S, Lapouble E, Laurence V, Michon J, Pierron G, Kovar H, Gaspar N, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, Corradini N, Bérard PM, Freedman ND, Rothman N, Dagnall CL, Burdett L, Jones K, Manning M, Wyatt K, Zhou W, Yeager M, Cox DG, Hoover RN, Khan J, Armstrong GT, Leisenring WM, Bhatia S, Robison LL, Kulozik AE, Kriebel J, Meitinger T, Metzler M, Hartmann W, Strauch K, Kirchner T, Dirksen U, Morton LM, Mirabello L, Tucker MA, Tirode F, Chanock SJ, Delattre O.

Nat Commun. 2018 Aug 9;9(1):3184. doi: 10.1038/s41467-018-05537-2.

10.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
11.

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, Lessnick SL.

Mol Cancer Ther. 2018 Sep;17(9):1902-1916. doi: 10.1158/1535-7163.MCT-18-0373. Epub 2018 Jul 11.

12.

Ewing sarcoma.

Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, Sorensen PH, Delattre O, Dirksen U.

Nat Rev Dis Primers. 2018 Jul 5;4(1):5. doi: 10.1038/s41572-018-0003-x. Review.

PMID:
29977059
13.

Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.

Jiménez I, Chicard M, Colmet-Daage L, Clément N, Danzon A, Lapouble E, Pierron G, Bohec M, Baulande S, Berrebi D, Fréneaux P, Coulomb A, Galmiche-Rolland L, Sarnacki S, Audry G, Philippe-Chomette P, Brisse HJ, Doz F, Michon J, Delattre O, Schleiermacher G.

Int J Cancer. 2019 Jan 1;144(1):68-79. doi: 10.1002/ijc.31620. Epub 2018 Oct 26.

PMID:
29923174
14.

PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis.

Kendall GC, Watson S, Xu L, LaVigne CA, Murchison W, Rakheja D, Skapek SX, Tirode F, Delattre O, Amatruda JF.

Elife. 2018 Jun 5;7. pii: e33800. doi: 10.7554/eLife.33800.

15.

Genetic predisposition to medulloblastomas: just follow the tumour genome.

Bourdeaut F, Delattre O.

Lancet Oncol. 2018 Jun;19(6):722-723. doi: 10.1016/S1470-2045(18)30289-4. Epub 2018 May 9. No abstract available.

16.

Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients.

Masliah-Planchon J, Lévy D, Héron D, Giuliano F, Badens C, Fréneaux P, Galmiche L, Guinebretierre JM, Cellier C, Waterfall JJ, Aït-Raïs K, Pierron G, Glorion C, Desguerre I, Soler C, Deville A, Delattre O, Michon J, Bourdeaut F.

Eur J Hum Genet. 2018 Aug;26(8):1217-1221. doi: 10.1038/s41431-018-0147-x. Epub 2018 Apr 30.

17.

NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma.

Garancher A, Lin CY, Morabito M, Richer W, Rocques N, Larcher M, Bihannic L, Smith K, Miquel C, Leboucher S, Herath NI, Dupuy F, Varlet P, Haberler C, Walczak C, El Tayara N, Volk A, Puget S, Doz F, Delattre O, Druillennec S, Ayrault O, Wechsler-Reya RJ, Eychène A, Bourdeaut F, Northcott PA, Pouponnot C.

Cancer Cell. 2018 Mar 12;33(3):435-449.e6. doi: 10.1016/j.ccell.2018.02.006.

18.

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E, Graillon T, Gentet JC, Delattre O, Chinot O, Padovani L.

Oncotarget. 2018 Jan 3;9(11):10175-10183. doi: 10.18632/oncotarget.23699. eCollection 2018 Feb 9.

19.

Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.

Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M.

Brain. 2018 May 1;141(5):1300-1319. doi: 10.1093/brain/awy039.

PMID:
29490009
20.

Transcriptomic definition of molecular subgroups of small round cell sarcomas.

Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer F, Bouvet M, Galmiche-Rolland L, Larousserie F, Longchampt E, Ranchere-Vince D, Pierron G, Delattre O, Tirode F.

J Pathol. 2018 May;245(1):29-40. doi: 10.1002/path.5053. Epub 2018 Mar 30.

PMID:
29431183
21.

The ALK receptor in sympathetic neuron development and neuroblastoma.

Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H.

Cell Tissue Res. 2018 May;372(2):325-337. doi: 10.1007/s00441-017-2784-8. Epub 2018 Jan 27. Review.

PMID:
29374774
22.

QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction.

Deveau P, Colmet Daage L, Oldridge D, Bernard V, Bellini A, Chicard M, Clement N, Lapouble E, Combaret V, Boland A, Meyer V, Deleuze JF, Janoueix-Lerosey I, Barillot E, Delattre O, Maris JM, Schleiermacher G, Boeva V.

Bioinformatics. 2018 Jun 1;34(11):1808-1816. doi: 10.1093/bioinformatics/bty016.

23.

Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.

Lopez-Delisle L, Pierre-Eugène C, Louis-Brennetot C, Surdez D, Raynal V, Baulande S, Boeva V, Grossetête-Lalami S, Combaret V, Peuchmaur M, Delattre O, Janoueix-Lerosey I.

Oncogene. 2018 Mar;37(11):1417-1429. doi: 10.1038/s41388-017-0039-5. Epub 2018 Jan 11.

24.

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.

Chicard M, Colmet-Daage L, Clement N, Danzon A, Bohec M, Bernard V, Baulande S, Bellini A, Deveau P, Pierron G, Lapouble E, Janoueix-Lerosey I, Peuchmaur M, Corradini N, Defachelles AS, Valteau-Couanet D, Michon J, Combaret V, Delattre O, Schleiermacher G.

Clin Cancer Res. 2018 Feb 15;24(4):939-949. doi: 10.1158/1078-0432.CCR-17-1586. Epub 2017 Nov 30.

25.

Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.

Guerrini-Rousseau L, Dufour C, Varlet P, Masliah-Planchon J, Bourdeaut F, Guillaud-Bataille M, Abbas R, Bertozzi AI, Fouyssac F, Huybrechts S, Puget S, Bressac-De Paillerets B, Caron O, Sevenet N, Dimaria M, Villebasse S, Delattre O, Valteau-Couanet D, Grill J, Brugières L.

Neuro Oncol. 2018 Jul 5;20(8):1122-1132. doi: 10.1093/neuonc/nox228.

26.

High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.

Chauvin C, Leruste A, Tauziede-Espariat A, Andrianteranagna M, Surdez D, Lescure A, Han ZY, Anthony E, Richer W, Baulande S, Bohec M, Zaidi S, Aynaud MM, Maillot L, Masliah-Planchon J, Cairo S, Roman-Roman S, Delattre O, Del Nery E, Bourdeaut F.

Cell Rep. 2017 Nov 14;21(7):1737-1745. doi: 10.1016/j.celrep.2017.10.076.

27.

Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome.

Hero B, Clement N, Øra I, Pierron G, Lapouble E, Theissen J, Pasqualini C, Valteau-Couanet D, Plantaz D, Michon J, Delattre O, Tardieu M, Schleiermacher G.

J Pediatr Hematol Oncol. 2018 Mar;40(2):93-98. doi: 10.1097/MPH.0000000000000976.

PMID:
29135842
28.

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.

Brisse HJ, Blanc T, Schleiermacher G, Mosseri V, Philippe-Chomette P, Janoueix-Lerosey I, Pierron G, Lapouble E, Peuchmaur M, Fréneaux P, Galmiche L, Algret N, Peycelon M, Michon J, Delattre O, Sarnacki S.

PLoS One. 2017 Sep 25;12(9):e0185190. doi: 10.1371/journal.pone.0185190. eCollection 2017.

29.

A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus.

Mobuchon L, Battistella A, Bardel C, Scelo G, Renoud A, Houy A, Cassoux N, Milder M, Cancel-Tassin G, Cussenot O, Delattre O, Besse C, Boland A, Deleuze JF, Cox DG, Stern MH.

NPJ Genom Med. 2017;2. pii: 5. doi: 10.1038/s41525-017-0008-5. Epub 2017 Mar 10.

30.

Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, Geoerger B, Orth MF, Grünewald TGP, Diaz E, Ducos B, Surdez D, Carcaboso AM, Medvedeva I, Deller T, Combaret V, Lapouble E, Pierron G, Grossetête-Lalami S, Baulande S, Schleiermacher G, Barillot E, Rohrer H, Delattre O, Janoueix-Lerosey I.

Nat Genet. 2017 Sep;49(9):1408-1413. doi: 10.1038/ng.3921. Epub 2017 Jul 24.

PMID:
28740262
31.

Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor.

Tauziède-Espariat A, Masliah-Planchon J, Brugières L, Puget S, Dufour C, Schneider P, Laquerrière A, Frebourg T, Bodet D, Lechapt-Zalcman E, Pierron G, Delattre O, Varlet P, Bourdeaut F.

Eur J Hum Genet. 2017 Oct;25(10):1170-1172. doi: 10.1038/ejhg.2017.115. Epub 2017 Jul 19.

32.

MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.

Musa J, Aynaud MM, Mirabeau O, Delattre O, Grünewald TG.

Cell Death Dis. 2017 Jun 22;8(6):e2895. doi: 10.1038/cddis.2017.244. Review.

33.

Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.

Colli LM, Machiela MJ, Zhang H, Myers TA, Jessop L, Delattre O, Yu K, Chanock SJ.

Cancer Res. 2017 Jul 1;77(13):3666-3671. doi: 10.1158/0008-5472.CAN-16-3338. Epub 2017 Apr 26.

34.

Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers.

Richer W, Masliah-Planchon J, Clement N, Jimenez I, Maillot L, Gentien D, Albaud B, Chemlali W, Galant C, Larousserie F, Boudou-Rouquette P, Leruste A, Chauvin C, Han ZY, Coindre JM, Varlet P, Freneaux P, Ranchère-Vince D, Delattre O, Bourdeaut F.

Oncotarget. 2017 May 23;8(21):34245-34257. doi: 10.18632/oncotarget.15939.

35.

Editorial overview: Characterizing the cancer genome: mechanistic insights and translational opportunities.

Delattre O, Bult CJ.

Curr Opin Genet Dev. 2017 Feb;42:78-80. doi: 10.1016/j.gde.2017.04.001. Epub 2017 Apr 15. No abstract available.

PMID:
28419908
36.

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.

Telomeres Mendelian Randomization Collaboration, Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S, Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret NC, Lund E, Duell EJ, Canzian F, Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FNG, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, Mckay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GM, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, Aben KK, Kiemeney LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE, Cho MH, Hui J, Ferreira MA, Thompson PJ, Morrison AC, Felix JF, Smith NL, Christiano AM, Petukhova L, Betz RC, Fan X, Zhang X, Zhu C, Langefeld CD, Thompson SD, Wang F, Lin X, Schwartz DA, Fingerlin T, Rotter JI, Cotch MF, Jensen RA, Munz M, Dommisch H, Schaefer AS, Han F, Ollila HM, Hillary RP, Albagha O, Ralston SH, Zeng C, Zheng W, Shu XO, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd ML, Davila S, Xie G, Siminovitch K, Bei JX, Zeng YX, Försti A, Chen B, Landi S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma SF, Foo JN, Liu J, Kim JW, Cox DG, Delattre O, Mirabeau O, Skibola CF, Tang CS, Garcia-Barcelo M, Chang KP, Su WH, Chang YS, Martin NG, Gordon S, Wade TD, Lee C, Kubo M, Cha PC, Nakamura Y, Levy D, Kimura M, Hwang SJ, Hunt S, Spector T, Soranzo N, Manichaikul AW, Barr RG, Kahali B, Speliotes E, Yerges-Armstrong LM, Cheng CY, Jonas JB, Wong TY, Fogh I, Lin K, Powell JF, Rice K, Relton CL, Martin RM, Davey Smith G.

JAMA Oncol. 2017 May 1;3(5):636-651. doi: 10.1001/jamaoncol.2016.5945.

37.

Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells.

Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, Dirksen U, Bouvier C, de Pinieux G, Snaar-Jagalska E, Chavrier P, Delattre O.

Oncogene. 2017 Jun 22;36(25):3505-3514. doi: 10.1038/onc.2016.498. Epub 2017 Jan 30.

38.

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.

Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schönegger A, Schuster M, Hadler J, Surdez D, Guillemot D, Lapouble E, Freneaux P, Champigneulle J, Bouvier R, Walder D, Ambros IM, Hutter C, Sorz E, Amaral AT, de Álava E, Schallmoser K, Strunk D, Rinner B, Liegl-Atzwanger B, Huppertz B, Leithner A, de Pinieux G, Terrier P, Laurence V, Michon J, Ladenstein R, Holter W, Windhager R, Dirksen U, Ambros PF, Delattre O, Kovar H, Bock C, Tomazou EM.

Nat Med. 2017 Mar;23(3):386-395. doi: 10.1038/nm.4273. Epub 2017 Jan 30.

39.

Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours.

Bertrand A, Rondenet C, Masliah-Planchon J, Leblond P, de la Fourchardière A, Pissaloux D, Aït-Raïs K, Lequin D, Jouvet A, Freneaux P, Sevestre H, Ranchere-Vince D, Tauziede-Espariat A, Maurage CA, Silva K, Pierron G, Delattre O, Varlet P, Frappaz D, Bourdeaut F.

Neuropathol Appl Neurobiol. 2018 Feb;44(2):224-228. doi: 10.1111/nan.12379. No abstract available.

PMID:
28054381
40.

Kids Enter the MATCH.

Schleiermacher G, Delattre O.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw305. Print 2017 May. No abstract available.

PMID:
28040695
41.

MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.

Missiaglia E, Shepherd CJ, Aladowicz E, Olmos D, Selfe J, Pierron G, Delattre O, Walters Z, Shipley J.

Cancer Lett. 2017 Jan 28;385:251-260. doi: 10.1016/j.canlet.2016.10.011. Epub 2016 Oct 29.

42.

Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.

Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, Bernard V, Fréneaux P, Michon J, Orbach D, Aerts I, Pacquement H, Bourdeaut F, Jiménez I, Thébaud E, Oudot C, Vérité C, Taque S, Owens C, Doz F, Le Tourneau C, Delattre O, Schleiermacher G.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26365. Epub 2016 Nov 29.

PMID:
27896933
43.

[Over-reduction after distal radius fracture pinning in young active patients: Prevention by multiple mixed pinning].

Delattre O, Greffe G, Stratan L, Duroux F, Donatien J.

Hand Surg Rehabil. 2016 Dec;35S:S89-S94. doi: 10.1016/j.hansur.2016.09.011. Epub 2016 Oct 20. Review. French.

PMID:
27890219
44.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
45.

68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.

Provost C, Prignon A, Cazes A, Combaret V, Delattre O, Janoueix-Lerosey I, Montravers F, Talbot JN.

Anticancer Res. 2016 Sep;36(9):4459-66.

PMID:
27630282
46.

Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.

Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, Lapouble E, Bellini A, Clement N, Iacono I, Bréjon S, Carrere M, Reyes C, Hocking T, Bernard V, Peuchmaur M, Corradini N, Faure-Conter C, Coze C, Plantaz D, Defachelles AS, Thebaud E, Gambart M, Millot F, Valteau-Couanet D, Michon J, Puisieux A, Delattre O, Combaret V, Schleiermacher G.

Clin Cancer Res. 2016 Nov 15;22(22):5564-5573. doi: 10.1158/1078-0432.CCR-16-0500. Epub 2016 Jul 20.

47.

EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.

Cidre-Aranaz F, Grünewald TG, Surdez D, García-García L, Carlos Lázaro J, Kirchner T, González-González L, Sastre A, García-Miguel P, López-Pérez SE, Monzón S, Delattre O, Alonso J.

Oncogene. 2017 Feb 9;36(6):766-776. doi: 10.1038/onc.2016.244. Epub 2016 Jul 4.

PMID:
27375017
48.

Cooperation between somatic mutations and germline susceptibility variants in tumorigenesis - a dangerous liaison.

Grünewald TG, Delattre O.

Mol Cell Oncol. 2015 Oct 6;3(3):e1086853. doi: 10.1080/23723556.2015.1086853. eCollection 2016 May.

49.

Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.

Ruiz-Pinto S, Pita G, Patiño-García A, García-Miguel P, Alonso J, Pérez-Martínez A, Sastre A, Gómez-Mariano G, Lissat A, Scotlandi K, Serra M, Ladenstein R, Lapouble E, Pierron G, Kontny U, Picci P, Kovar H, Delattre O, González-Neira A.

Ann Oncol. 2016 Sep;27(9):1788-93. doi: 10.1093/annonc/mdw234. Epub 2016 Jun 10.

PMID:
27287205
50.

Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A.

Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.

Supplemental Content

Loading ...
Support Center